Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
TORM (NASDAQ: TRMD, TRMD A) reported insider transactions by CEO and executive director Jacob Balslev Meldgaard. He exercised 170,133 restricted share units in TORM shares (ISIN: GB00BZ3CNK81) on 20 May 2026 for DKK 23,495,361 outside a trading venue.
Meldgaard also sold an aggregated 549,177 shares on Nasdaq Copenhagen on 18 and 20 May 2026 at prices around DKK 205–207 per share, for total proceeds of DKK 112,829,967.
Agilent (NYSE:A) declared a quarterly cash dividend of $0.255 per share of common stock. The dividend is payable on July 22, 2026 to shareholders of record as of June 30, 2026. Agilent reported $6.95 billion in fiscal 2025 revenue and employs about 18,000 people worldwide.
TORM (NASDAQ: TRMD, TRMD A) increased its share capital on May 20, 2026 through the exercise of Restricted Share Units. A total of 215,635 new A-shares were issued with a nominal value of USD 2,156.35.
According to TORM, 14,206 shares were subscribed at DKK 0.07 per share, 85,067 at DKK 131.80, and 116,362 at DKK 144.40. The capital increase was executed without pre-emption rights. After the transaction, share capital totals USD 1,023,389.74, divided into 102,338,974 A-shares of USD 0.01 each.
Agilent (NYSE:A) announced a TSA contract to deploy its new Bulk Alarm Resolution Technology (BRT) at U.S. airport security checkpoints in FIFA World Cup 2026 host cities.
The BRT uses Surface Offset Raman Spectroscopy and algorithms to quickly confirm liquids, gels, creams, solids, and powders through various containers, aiming to enhance detection, efficiency, and traveler experience.
The Board of Directors of Crawford & Company (NYSE: CRD-A, CRD-B) approved a quarterly cash dividend of $0.075 per share on both Class A and Class B common stock. The dividend will be paid on June 12, 2026 to shareholders of record on May 29, 2026.
Agilent (NYSE:A) will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, at 9:20 a.m. EDT in New York City.
A live audio webcast and replay will be available on Agilent’s investor relations website. Agilent reported $6.95 billion fiscal 2025 revenue and employs about 18,000 people.
Agilent (NYSE: A) named Michael Buckner as chief legal officer, effective May 4, 2026. Buckner brings nearly three decades of senior global legal experience across mergers and acquisitions, antitrust, intellectual property and regulatory matters.
He joins from Danaher, where he led M&A legal strategy including the Abcam acquisition and Veralto spin-off. Agilent reported fiscal 2025 revenue of $6.95 billion and about 18,000 employees.
Agilent (NYSE: A) will report second-quarter fiscal 2026 results after the market close on May 27, 2026 and will host a listen-only conference call webcast at 1:30 p.m. PDT the same day. A recording will be available on the investor website for 90 days.
Agilent reported $6.95 billion revenue for fiscal 2025 and employs about 18,000 people worldwide. Webcast access is via the Events section of Agilent's Investor Relations site.
TORM plc (A) held its Annual General Meeting on 15 April 2026 where all resolutions were passed on a poll with 52.83% turnout (53,955,672 votes of 102,123,339 eligible).
Notable outcomes: Annual Report approved, auditor reappointed, buyback resolutions passed (Contract A: 99.59% for; Contract B: 73.30% for), and the Board confirmed quarterly dividend policy and a Q4 interim dividend paid 25 March 2026.
The Board noted >20% votes against Resolutions 2, 3 and 12 and will consult shareholders to understand concerns.
Agilent (NYSE: A) will showcase cancer research solutions at the AACR Annual Meeting in San Diego, April 17–22, 2026. Highlights include the new BioTek Cytation 9, an AI-enabled preview for xCELLigence RTCA eSight, SureSelect compatibility with Oxford Nanopore long-read sequencing, and user events.
Agilent will exhibit at booth 4527 and continue support for early-career researchers via AACR Foundation initiatives.